Comparative Pharmacology
Head-to-head clinical analysis: TECENTRIQ HYBREZA versus XPOVIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECENTRIQ HYBREZA versus XPOVIO.
TECENTRIQ HYBREZA vs XPOVIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Programmed death-ligand 1 (PD-L1) blocking antibody that binds to PD-L1, preventing interaction with PD-1 and B7.1, thereby reactivating antitumor immune responses.
Selective inhibitor of nuclear export (SINE) that binds to and inhibits exportin 1 (XPO1), blocking the nuclear export of tumor suppressor proteins (e.g., p53, IκB) and growth regulators, leading to their nuclear accumulation and reactivation, thereby inducing apoptosis in cancer cells.
840 mg intravenously every 2 weeks, or 1200 mg intravenously every 3 weeks, or 1680 mg intravenously every 4 weeks.
XPOVIO (selinexor) is administered orally at a dose of 80 mg (four 20 mg tablets) on days 1 and 3 of each week for multiple myeloma. For diffuse large B-cell lymphoma, the recommended dose is 60 mg (three 20 mg tablets) on days 1 and 3 of each week.
None Documented
None Documented
Terminal elimination half-life is approximately 6.5 days (range 4–9 days), supporting a subcutaneous dosing interval of every 3 weeks.
Terminal half-life ranges from 6 to 10 hours (mean ~7.5 h) in patients with relapsed/refractory multiple myeloma; supports twice-weekly dosing with food.
Almost entirely renal as unchanged drug (approximately 90% of a subcutaneously administered dose is eliminated via the kidneys within 96 hours). Biliary/fecal elimination accounts for less than 1%.
Primarily metabolized by CYP3A4 and other pathways; <1% excreted unchanged in urine; fecal excretion accounts for ~80% of total clearance, with renal elimination minimal (<2% of dose).
Category C
Category C
Antineoplastic, PD-L1 Inhibitor
Antineoplastic